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Abstract We recently showed that estrogen induces expression
of the anti-apoptotic protein, Bcl-2 in MCF-7 human breast
cancer cells. Since estrogen-dependent breast tumours can
regress following estrogen withdrawal, we hypothesized that
stable Bcl-2 expression would prevent estrogen-withdrawal
induced regression of MCF-7 tumours. We therefore established
tumours in ovariectomized female nude mice implanted with an
estrogen-release pellet using untransfected MCF-7 cells or MCF-
7 cells stably transfected with a Bcl-2 cDNA sense or antisense
expression vector. All tumours grew at similar rates indicating
that Bcl-2 levels have no effect on tumour formation. After
removal of the estrogen pellet, Bcl-2 antisense tumours and
untransfected MCF-7 tumours regressed means of 49% and
52%, respectively, after estrogen pellet removal whereas Bcl-2
sense tumours were significantly stabilized. Regressing tumours
displayed characteristics of apoptotic cells. These results show
that Bcl-2 can prevent hormone-dependent breast tumour
regression and are consistent with the notion that decreased
Bcl-2 levels following estrogen withdrawal renders hormone-
dependent breast tumour cells sensitive to apoptotic regression.
z 1998 Federation of European Biochemical Societies.
Key words: Bcl-2; Apoptosis; Breast tumour; Estrogen;
Regression
1. Introduction
Many hormone dependent tumours including estrogen re-
ceptor positive human breast cancer tumours respond to hor-
mone deprivation by growth cessation and regression [1]. This
observation has led to the widespread use of antiestrogens in
the treatment of hormone-dependent breast cancer. An impor-
tant experimental model for mammary tumour regression has
utilized the ability of estrogen receptor positive human breast
cancer cells to form hormone-dependent tumours in nude
mice. These tumours respond to antiestrogen treatment by
growth cessation [2] or in some cases, regression [3,4]. Estro-
gen ablation by ovariectomy and deprivation by removal of
implanted estrogen pellets induces regression of these tumours
through the process of programmed cell death or apoptosis
[5].
Apoptosis is an active process involving complex molecular
signalling events which are yet to be fully understood. Mor-
phologically, apoptosis can be de¢ned by a number of char-
acteristics including chromatin condensation, plasma mem-
brane blebbing and nuclear fragmentation [6]. Often, but
not always, apoptosis is accompanied by the activation of
endonucleases which cleave genomic DNA into nucleosomal
length fragments producing free 3P hydroxyl ends that can be
detected by DNA end-labelling procedures [7]. A critical com-
ponent of the apoptotic cascade is a family of cysteine pro-
teases (caspases) which consists of over 10 cellular members
(reviewed in [8]).
A number of molecules which either positively or negatively
regulate apoptosis have been identi¢ed. Bcl-2 is among the
best studied of these proteins. When expressed at su⁄ciently
high levels, Bcl-2 can suppress apoptosis induced by a wide
variety of insults and stimuli [9,10]. Both Bcl-2 family mem-
bers as well as unrelated molecules regulate apoptosis. For
example Bax, Bak and BAD promote apoptosis while Bcl-
xL, Mcl-1 and BAG-1 suppress cell death (reviewed in
[11,12]). It is not completely understood how Bcl-2 family
members regulate apoptosis, however, recent evidence sug-
gests that these proteins can form channels which may partic-
ipate in the mitochondrial permeability transition which oc-
curs during apoptosis (reviewed in [12]).
We recently showed that estrogen can induce expression of
Bcl-2 mRNA and protein in human estrogen receptor positive
MCF-7 breast cancer cells [13]. Bcl-2 expression in untreated
breast cancer is thus generally associated with a good prog-
nosis based on its association with a di¡erentiated, estrogen
receptor positive, EGF-receptor negative phenotype [14]. Es-
trogen is required to support the growth of hormone-depend-
ent breast cancer cells in vivo. Ablation or treatment with
antiestrogen can induce regression of these tumours; however,
little is known about the mechanisms involved. In this study
we wished to determine if expression of Bcl-2 can prevent
estrogen ablation-induced tumour regression in vivo. The re-
sults show that reduced Bcl-2 levels in either untransfected
MCF-7 cells or in antisense-Bcl-2 transfected cells permits
tumour regression following estrogen-pellet removal whereas
elevated Bcl-2 signi¢cantly prevents regression in this model.
Our ¢ndings thus support the hypothesis that stable Bcl-2
expression can prevent breast tumour regression and are con-
sistent with the notion that the decrease in Bcl-2 levels follow-
ing estrogen withdrawal permits tumour regression.
2. Materials and methods
2.1. Tumour growth in nude mice
Six week-old ovariectomized female nude mice (nu/nu CD-1) were
implanted subcutaneously with an estrogen release pellet (60 day re-
lease pellet containing 0.72 mg L-estradiol, Innovative Research of
America, Sarasota, FL, USA). Two days later three pooled clones
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of exponentially growing MCF-7 cells expressing either the sense ori-
entation or the antisense orientation of Bcl-2 (MCF-7(Bcl-2S) or
MCF-7(Bcl-2AS)) [13] were trypsinized and three million cells were
injected subcutaneously into the £anks of the animals. In seven of the
animals, MCF-7(Bcl-2AS) cells were injected in one £ank while MCF-
7(Bcl-2S) cells were injected in the contralateral £ank. To rule out the
potential in£uence of factors released by non-regressing tumours on
matched tumours in the contralateral £ank following estrogen pellet
removal, we also injected three animals with MCF-7(Bcl-2AS) cells on
both sides and two animals with MCF-7(Bcl-2S) cells on both sides.
Four animals were inoculated on one side only with MCF-7(Bcl-2AS)
cells and four were inoculated on one side only with MCF-7(Bcl-2S)
cells. Five tumours were also generated using untransfected MCF-7
cells. In order to assess the estrogen dependence of tumour growth,
four inoculations of MCF-7(Bcl-2S) and four of MCF-7(Bcl-2AS)
were performed in sham operated mice which did not receive an estro-
gen pellet. Tumours were allowed to grow to an average of 300 mm3
before removal of the estrogen pellet. Estrogen pellets were left in four
animals inoculated with MCF-7(Bcl-2S) cells for the duration of the
experiment.
2.2. Growth measurements
Tumour size was calculated every 3 days using calipers to measure
length, width and height of the tumour. The tumour volumes were
then calculated according to the formula V = 1/2 (4Z/3)(l/2)(w/2)(h),
where l = length, w = width and h = height [15].
2.3. In situ end labelling (ISEL)
ISEL was performed essentially as described by Fliss and Gattinger
[16]. Frozen cryostat sections were thawed and ¢xed in 1% glutaral-
dehyde. Free 3P hydroxyl ends were labelled with biotin-16 dUTP
(Boehringer Mannheim, Canada) using terminal transferase. Labelled
ends were detected by incubation in avidin conjugated-£uoroscein
isothiocyanate. Following application of antifade solution, slides
were coverslipped and photographed using a £uorescence microscope
equipped with a 35-mm camera.
2.4. Immunohistochemistry
Tumour specimens derived at various times after removal of the
estrogen pellet were ¢xed in zinc-bu¡ered formalin and embedded in
para⁄n. After sectioning (5 Wm), depara⁄nized sections were pre-
treated by heating in a microwave before incubating with antisera
against Bcl-2 family members. Typically, antibodies were diluted
1:500 to 1:1000 (v/v) for polyclonal antibodies Bcl-2 [17], Bax [18],
Bcl-x [19], Mcl-1 [20] and Bak [21] and 1:100 of acites for the BAG-1
monoclonal antibody [22]. Proteins were visualized using the avidin-
biotin complex diaminobenzidine-based detection method as described
in detail elsewhere [17]. Nuclei were counterstained with hematoxylin
and closed with De-Pe-X (Fluka, Germany) mounting medium. For
all antibodies, the immunostaining procedure was performed in par-
allel using preimmune serum and in some cases preadsorbed antise-
rum with 5^10 Wg/ml of the synthetic peptide immunogen or recombi-
nant protein to verify antibody speci¢city. The immunostaining results
were arbitrarily scored according to intensity as 0, negative; 1+,
weak; 2+, moderate; 3+, strong; 4+, very intense. Results presented
for each tumour were based on analysis of serially sectioned slides
stained in a minimum of two separate experiments.
2.5. Immunoblotting
Un¢xed tissues were snap-frozen and pulverized under liquid N2.
Following the addition of RIPA bu¡er, samples were sonicated and
incubated for 30 min on ice, then centrifuged at 16 000Ug for 20 min
to remove insoluble protein. Immunoblotting was performed as pre-
viously described [13]. Densitometry was performed on immunoblots
using the microcomputer imaging densitometry (MCID) software sys-
tem (Imaging Research, Brock University, St. Catherines, Ont., Can-
ada). Arbitrary density units for each immunoreactive protein band
were then normalized to actin band density on the same gel by divid-
ing density units for each band by the density of the actin band in the
same lane.
2.6. DNA fragmentation assay
Tumours were homogenized in a bu¡er containing 10 mM Tris-
HCl, 25 mM EDTA and 100 mM NaCl then lysed and centrifuged
after making the slurry 1% with sodium dodecyl sulfate. DNA frag-
ments were precipitated from the supernatant, phenol/chloroform ex-
tracted, reprecipitated then treated with RNase prior to agarose gel
electrophoresis.
3. Results
3.1. Bcl-2 prevents estrogen ablation-induced tumour regression
Since our previous ¢ndings have shown that estrogen in-
duces Bcl-2 production in MCF-7 cells, we wished to test the
hypothesis that constitutive expression of Bcl-2 might prevent
estrogen ablation-induced tumour regression. Since Bcl-2 anti-
sense expression does not alter the growth of MCF-7 cells in
the presence of E2, we used Bcl-2(AS) cells as a control for
the Bcl-2(S) clones.
Since most mice had bilateral tumours, estrogen pellets
were removed when the largest tumour reached approximately
300 mm3. In most cases, one tumour (either sense or anti-
sense) reached this volume before the other regardless of
what combination of tumours were present in the mouse.
The time to reach maximum tumour volume was also variable
between animals and was independent of tumour type. Fur-
thermore, regression of tumours, indicated in Fig. 1, was not
dependent on the tumour volume at the time of estrogen pellet
removal or the combination of tumour types present in the
mouse. Animals were sacri¢ced after a mean of 17 þ 3 days
following estrogen pellet removal. Tumours allowed to regress
signi¢cantly longer than this became too small to perform
immunohistochemical analysis. There was no signi¢cant dif-
ference between average tumour volumes for matched sets of
MCF-7(Bcl-2S and AS) tumours grown in the same mouse
(273 þ 72 mm3 for Bcl-2(S) and 264 þ 42 mm3 for Bcl-
2(AS)). Together these data show that there is no di¡erence
between the growth of Bcl-2 sense and antisense tumours in
the presence of estrogen.
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Fig. 1. Tumour regression following estrogen pellet removal. MCF-
7(Bcl-2S): n = 14, and MCF-7(Bcl-2AS): n = 15 and untransfected
MCF-7: n = 5. Final tumour volumes at tumour removal were div-
ided by tumour volumes at removal of the estrogen pellet. Bars rep-
resent standard error. Asterisks indicate signi¢cant di¡erences in ¢-
nal tumour volumes between both MCF-7(Bcl-2AS) (P6 0.001) and
MCF-7 untransfected tumours (P6 0.04) and MCF-7(Bcl-2S) tu-
mours (one-tailed t-test).
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After removal of the estrogen pellet clear di¡erences in the
behaviour of Bcl-2 sense and antisense tumours were noted.
Fig. 1 shows the mean ratios of tumour volumes at the time of
estrogen pellet removal to the volume at the time of tumour
removal. Mean volumes for Bcl-2(AS) tumours at the termi-
nation of the experiment were less than 50% of the volume of
the tumour at estrogen pellet removal and all MCF-7 untrans-
fected control tumours regressed to a similar extent (mean
52%). Strikingly, the Bcl-2(S) tumour volumes at the time of
tumour harvest remained signi¢cantly stabilized compared
with their volumes at E2 pellet removal.
No regression was observed unless the estrogen release pel-
let was removed indicating that regression was dependent on
estrogen ablation (data not shown). Four MCF-7(Bcl-2S) tu-
mours were also grown with an estrogen pellet present
throughout the entire experiment. These tumours also grew
continuously and were used for studies of Mcl-1 expression
(see below).
If decreased Bcl-2 expression is critical for regression then
wild-type MCF-7 cells which consistently regress following E2
withdrawal should contain reduced levels of Bcl-2 following
pellet removal. To determine this we removed MCF-7 tu-
mours at the time of removal of the E2 pellet and on several
days thereafter. Immunoblot analysis of extracts from these
tumours in Fig. 2 shows that, as expected, Bcl-2 levels were
highest in the tumour exposed to E2. Levels declined rapidly
between days 2 and 3 and remained low after pellet removal.
3.2. Regressing tumours but not stable tumours undergo
programmed cell death
To determine if Bcl-2 expression prevented apoptosis in
stable tumours, we performed several assays to detect dying
and apoptotic cells. First, sections from regressing Bcl-2 anti-
sense and stable Bcl-2 sense tumours were assayed for the
presence of oligonucleosomal length DNA, a hallmark of
apoptosis. This was determined by the labelling of free 3P
DNA ends using terminal deoxynucleotidyl transferase. Typ-
ical results presented in Fig. 3A show that antisense tumours
contain a large number of nuclei which can be labelled in the
transferase reaction whereas Bcl-2(S) tumours display virtu-
ally no in situ end labelling (Fig. 3b). When the percentage of
labelled nuclei in sections from six Bcl-2(AS) and ¢ve Bcl-2(S)
was calculated, regressing tumours contained signi¢cantly
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Fig. 3. In situ end labelling and DNA fragmentation assay in
MCF-7 tumour sections. In situ end labelling was performed as de-
scribed in Section 2 to detect free 3P hydroxyl groups indicative of
apoptosis. Sections are from: (A) a representative regressing MCF-
7(Bcl-2AS) and (B) a stable MCF-7(Bcl-2S) tumour. C: DNA from
a stable MCF-7(Bcl-2S) tumour (lane 1) and two regressing MCF-
7(Bcl-2AS) tumours (lanes 2 and 3) was assayed for the presence of
oligonucleosomal length DNA ladders. M: lambda HindIII digest
and IRT: irradiated rat thymocytes.
Fig. 2. Estrogen withdrawal decreases Bcl-2 expression in MCF-7
tumours. Extracts from control (C) MCF-7 tumours at the time of
E2 pellet removal (+E2), and at days 2, 3, 5 and 18 following pellet
removal (3E2) were subjected to immunoblot analysis with Bcl-2
antibody. Reactivity with actin antibody was used as a loading con-
trol.
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more labelled nuclei than the stable Bcl-2(S) tumours
(mean þ S.E., 3.0 þ 0.6% vs. 1.1 þ 0.3%, respectively, P6
0.05, t-test). Secondly, we assessed these tumours for the pres-
ence of oligonucleosomal length DNA fragments. Fig. 3C
shows that the DNA ‘laddering’ pattern can be seen in two
regressing antisense tumours following estrogen pellet removal
but not in a non-regressing MCF-7(Bcl-2S) tumour. Together
these results show that tumour stability is associated with an
inhibition of apoptosis.
3.3. Expression of Bcl-2 is insu⁄cient for tumorigenesis
Inoculation of ovariectomized mice which had been sham
operated but did not receive an estrogen pellet with MCF-
7(Bcl-2(AS)) cells (four inoculations) or MCF-7(Bcl-2(S)) cells
(four inoculations) did not produce tumours indicating that
Bcl-2 is insu⁄cient for permitting tumour growth in the ab-
sence of estrogen.
3.4. Expression of apoptotic proteins in Bcl-2 sense and
antisense tumours
We wished to con¢rm the constitutive expression of Bcl-2 in
sense tumours in vivo and to determine whether changes in
the expression of other apoptosis-regulating proteins occur in
tumours which might contribute to their regression or stabil-
ization. We therefore evaluated the levels of Bcl-2, Bax, Mcl-
1, BAG-1, Bak and Bcl-x by immunohistochemistry on sec-
tions from each tumour (Fig. 4). As expected, all sense Bcl-2
tumours exhibited intense Bcl-2 immunostaining (mean þ S.D.
of 3.57 þ 0.46 on the relative scale) while antisense tumours
contained little or small amounts of Bcl-2 immunoreactivity
(mean 0.44 þ 0.56) (Fig. 4A).
No signi¢cant di¡erences between the immunointensity
scores of all of the other apoptosis regulatory proteins were
detected in sense vs. antisense tumours except for Mcl-1 (Fig.
4C). Mcl-1 levels varied in a reciprocal manner with respect to
Bcl-2 expression. While Bcl-2 antisense tumour cells contained
Mcl-1 immunostaining at moderate to high levels (mean
1.94 þ 0.50), Bcl-2 sense tumours expressed this protein at sig-
ni¢cantly lower levels (mean 1.27 þ 0.37, P6 0.001, unpaired
t-test). Importantly, while Bcl-2 antisense tumours exhibited
homogeneous immunostaining for Mcl-1, Bcl-2 sense tumours
were generally comprised of fewer than 50% Mcl-1 immuno-
positive cells (not shown).
Both Bax and Bcl-x expression were easily detectable by
immunohistochemical analysis in Bcl-2 sense and antisense
tumours. No signi¢cant di¡erence between Bcl-2(S) and
(AS) immunointensity for either of these proteins was ob-
served (Fig. 4B and F, (Bax) and (Bcl-x), respectively),
although Bax immunointensity was slightly higher (P = 0.06)
in Bcl-2(S) expressing tumours compared with (AS) tumours
(mean scores of 1.93 þ .46 and 1.65 þ 0.39, respectively). Bcl-x
was expressed at a mean immunointensity level of 2.23 þ 0.56
in Bcl-2(S) tumours compared with 2.50 þ 0.40 in Bcl-2(AS)
tumours. Bak immunostaining also was not signi¢cantly dif-
ferent in the two types of tumour (means of 1.17 þ 0.49 (Bcl-
2(S) and 1.44 þ 0.46 (Bcl-2(AS)). We observed high levels of
Bak immunostaining in ¢broblasts and macrophages which
had in¢ltrated and surrounded sections of the tumour con-
¢rming that the low levels of Bak observed in tumours did not
re£ect an artifact of the staining procedure (Fig. 4D). BAG-1
immunostaining was essentially the same in Bcl-2(S) and Bcl-
2(AS) tumours (means of 0.93 þ 0.26 and 0.97 þ 0.41, respec-
tively) (Fig. 4E).
Sections of tumours were also stained with preimmune se-
rum corresponding to each of the indicated antibodies. In all
instances sections were negative for immunoreactivity with
preimmune serum (not shown), thus con¢rming the speci¢city
of these results.
To ensure that our visual assessment by immunohistochem-
istry of the apoptosis regulatory protein expression in tumours
was accurate, we performed immunoblot analysis of these
proteins using lysates derived from each tumour followed by
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Fig. 4. Immunostaining of MCF-7(Bcl-2S and AS) tumours. Zinc-bu¡ered formalin-¢xed, para⁄n-embedded tumours were sectioned and im-
munostained with antisera speci¢c for apoptosis regulatory proteins. A summary of immunohistochemical analysis of apoptotic proteins in
MCF-7(Bcl-2S) and MCF-7(Bcl-2AS) tumours scored as described in Section 2. Serial sections of all tumours were stained with antibodies
against human (A) Bcl-2; (B) Bax; (C) Mcl-1; (D) Bak; (E) Bag-1; and (F) Bcl-x. Individual tumours are represented by each point. When
more than seven tumours scored the same intensity the point is preceded by the number of tumours in parentheses.
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densitometric quanti¢cation. Consistent with the immunohis-
tochemistry, immunoblot analysis did not detect signi¢cant
di¡erences between sense and antisense tumours for Bak or
Bcl-x or BAG-1 expression (not shown). Also in agreement
with immunointensity results, the immunoblot analysis in Fig.
5A shows that Mcl-1 protein levels in Bcl-2(S) tumours ap-
peared reduced. Densitometric analysis of Mcl-2 corrected for
actin resulted in mean values þ S.D. of 1.02 þ 0.19 for Bcl-
2(AS) and 0.70 þ 0.13 for Bcl-2(S), indicating a signi¢cant
di¡erence in Mcl-1 expression between Bcl-2(S) and Bcl-
2(AS) (P6 0.05; Student’s t-test). In the absence of E2, Bcl-
2(AS) and untransfected MCF-7 cells contain similar levels of
Bcl-2 (not shown). Accordingly, Fig. 5B shows that Mcl-1
levels were also elevated in regressing untransfected MCF-7
tumours compared with Bcl-2(S) tumours.
Since the results of immunohistochemistry suggested a
small but not statistically signi¢cant increase in Bax levels in
Bcl-2(S) tumours, the blot in Fig. 5A was also incubated with
anti-Bax antibody. While omission of the ¢rst lane containing
a Bcl-2(AS) sample yielded a mean density value of 0.60 þ 0.16
which is signi¢cantly elevated (P6 0.05, Student’s t-test) com-
pared with Bcl-2(S) tumours (mean 0.83 þ 0.10), inclusion of
the ¢rst Bcl-2(AS) value rendered the di¡erences insigni¢cant.
These results suggest that a subset of Bcl-2(S) tumours do
contain elevated Bax levels.
Previous studies have suggested that Mcl-1 may be a weak
‘short term’ anti-death protein, allowing the cell a brief win-
dow of survival following cell di¡erentiation or responses to
death signals [23]. Since a variety of cell death stimuli have
been reported to induce transient increases in Mcl-1 [24], we
wondered whether estrogen withdrawal itself or the expression
of Bcl-2 in£uences Mcl-1 expression. We therefore compared
Mcl-1 levels in four Bcl-2(S) tumours grown continuously in
the presence of the estrogen pellet with those of four Bcl-2(S)
tumours which had been allowed to remain in the animal for
15 days following estrogen pellet removal. The results indi-
cated that the level of Mcl-1 did not vary in Bcl-2(S) tumours
whether or not they were grown continuously in the presence
of estrogen (not shown). Thus, Bcl-2 expression, not estrogen,
appears to somehow repress Mcl-1 expression in these breast
tumour cells.
4. Discussion
It has been known for many years that estrogen ablation
results in breast tumour regression; however, the underlying
mechanism is not known. We previously demonstrated that
Bcl-2 expression is under the control of estrogen in MCF-7
breast cancer cells. We thus postulated that estrogen with-
drawal might result in apoptosis, in part, by lowering Bcl-2
levels. In the present study we show that MCF-7 and MCF-
7(Bcl-2AS) tumours expressing little or no Bcl-2 undergo es-
trogen-ablation induced cell death. In contrast most tumours
which constitutively express high levels of Bcl-2 are resistant
to the regression inducing e¡ects of estrogen withdrawal. It
should be pointed out that ectopically expressed Bcl-2 levels
were higher than physiological levels in the presence of E2
(estimated by comparison between control MCF-7 in Fig. 2
to Bcl-2(S) samples in Fig. 4), and it is a formal possibility
that these levels were a factor in prevention of regression.
However, insofar as Bcl-2(S) clones behave similarly to con-
trol MCF-7 cells with respect to tumour formation and stabil-
ization of tumours after E2 withdrawal was associated with
reduced apoptosis, Bcl-2 appears to function primarily in an
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Fig. 5. A: Analysis of apoptotic regulatory proteins from MCF-7 tumours. Extracts from sets of contralateral tumours (pairs from left to right)
were analyzed by immunoblot for expression of Bcl-2, Mcl-1 and Bax. Samples are marked A, antisense and S, sense. B: Analysis of Mcl-1 in
untransfected MCF-7 tumours. Extracts from ¢ve regressing MCF-7 tumours, a Bcl-2(AS) and a Bcl-2(S) tumour were subjected to immuno-
blot analysis for Mcl-1 expression.
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anti-apoptotic capacity in these cells. Thus, estrogen depriva-
tion in vivo results in one or more death signals which can be
inhibited by Bcl-2 in breast cancer cells.
Bax immunoreactivity displayed a range of intensities in a
high proportion of cells. In some Bcl-2 expressing tumours,
Bax expression was higher than in antisense tumours, perhaps
re£ecting the ability of Bcl-2 to stabilize the Bax protein [25]
or the ability of cells with higher Bax levels to survive and
accumulate in tumours where Bcl-2 is provided. In addition,
the expression of both proapoptotic Bax and Bak in MCF-7
cells might render them exquisitely susceptible to estrogen
deprivation induced cell death in the absence of Bcl-2. Over-
all, the absence of changes in any of the other pro- or anti-
apoptotic proteins in regressing or stable tumours, respec-
tively, suggests that alterations in Bcl-2 expression are su⁄-
cient to regulate estrogen-withdrawal induced breast tumour
regression.
A striking inverse correlation between Bcl-2 and Mcl-1 ex-
pression was observed in the tumours. Mcl-1 was ¢rst de-
scribed as a transiently induced Bcl-2 related protein in di¡er-
entiating human myeloid leukemia cells [26]. In complex
epithelial tissues, Bcl-2 and Mcl-1 are expressed in opposing
gradients. In the latter, Bcl-2 is expressed in less di¡erentiated
cells while Mcl-1 is expressed in the more di¡erentiated cells
[27]. More recently Mcl-1 has been shown to be an early
response gene, induced rapidly by signals for either cell di¡er-
entiation or death. Consequently, it has been speculated that
Mcl-1 may play a role as a ‘short term e¡ector of viability’,
allowing the cell a brief period of time to make decisions
regarding the ultimate response to a death inducing signal
[28]. In this context, Mcl-1 may partially substitute for Bcl-2
in those tumours which express little or no Bcl-2 although it is
clearly unable to prevent regression-associated apoptosis.
In summary, low Bcl-2 levels mediated by antisense tran-
script expression and/or estrogen withdrawal are associated
with regression of MCF-7 tumours following estrogen with-
drawal. Stable Bcl-2 expression can prevent tumour regression
following estrogen withdrawal consistent with the notion that
estrogen promotes the survival of hormone-dependent breast
cancer cells at least in part by increasing Bcl-2 expression.
Thus, the reduction of Bcl-2 levels by antiestrogens or ovar-
iectomy likely plays a role in the process of regression of
hormone-dependent adenocarcinomas of the breast by render-
ing the cells sensitive to apoptotic stimuli that occur as a
result of E2 deprivation. It will be important to extend these
observations to additional estrogen-dependent human breast
lines and primary tumours in animal models to further de¢ne
the role of Bcl-2 in tumour regression.
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